RPGLIFE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 60/100 — Quality 79 · Valuation 36 · Momentum 56
| Share price | ₹3,017.10 |
| Market cap | ₹4,725 Cr |
| P/E ratio | 41.0 |
| P/B ratio | 7.8 |
| ROE | 20.5% |
| ROCE | 24.5% |
| Dividend yield | 0.90% |
| Book value | ₹366.01 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹708 Cr | ₹115 Cr | 21.0% |
| 2025 | ₹653 Cr | ₹183 Cr | 25.0% |
| 2024 | ₹577 Cr | ₹88 Cr | 19.4% |
| 2023 | ₹509 Cr | ₹68 Cr | 17.5% |
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthoped